Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson’s disease

Related Articles:

• The inflammasome field is heating up December 6, 2019   When a cell is sick or damaged it will send out signals alerting the immune system that something is wrong. If enough of these molecules are released, they will initate an “immune response” and this process is called inflammation. There is evidence in neurodegenerative conditions (like Parkinson’s and Alzheimer’s) that the inflammation process is involved, and inhibitors of particular…
• Does immunotherapy need therapy? June 12, 2021 # # # # Over the last decade, a large number of clinical trials involving immunotherapy have been conducted in the field of Alzheimer’s research. The overall success rate of these studies has not been encouraging. Immunotherapy involves artificially boosting the immune system so that it targets of particular pathogen – like a rogue protein in the case of Alzheimer’s…
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The age-associated changes of PARKIN January 28, 2021 # # # # Tiny variations in a region of DNA referred to as “Parkin” are associated with an increased risk of developing Parkinson’s (particularly young onset forms of the conditions). The Parkin DNA provide the instructions for making a protein that is involved with many functions inside cells. New research indicates that as we age, Parkin protein becomes less…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson's disease August 4, 2022 Neuron. 2022 Aug 3;110(15):2356-2358. doi: 10.1016/j.neuron.2022.06.015.ABSTRACTNLRP3 is a central driver of neurodegeneration thought to function mainly in microglia. In this issue of Neuron, Panicker et al. (2022) find that NLRP3 is a parkin substrate that contributes significantly to Parkinson's disease pathogenesis by acting in neurons.PMID:35926449 | DOI:10.1016/j.neuron.2022.06.015
• Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson's disease August 4, 2022 Neuron. 2022 Aug 3;110(15):2356-2358. doi: 10.1016/j.neuron.2022.06.015.ABSTRACTNLRP3 is a central driver of neurodegeneration thought to function mainly in microglia. In this issue of Neuron, Panicker et al. (2022) find that NLRP3 is a parkin substrate that contributes significantly to Parkinson's disease pathogenesis by acting in neurons.PMID:35926449 | DOI:10.1016/j.neuron.2022.06.015
• Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson's disease August 4, 2022 Neuron. 2022 Aug 3;110(15):2356-2358. doi: 10.1016/j.neuron.2022.06.015.ABSTRACTNLRP3 is a central driver of neurodegeneration thought to function mainly in microglia. In this issue of Neuron, Panicker et al. (2022) find that NLRP3 is a parkin substrate that contributes significantly to Parkinson's disease pathogenesis by acting in neurons.PMID:35926449 | DOI:10.1016/j.neuron.2022.06.015
• Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson's disease August 4, 2022 Neuron. 2022 Aug 3;110(15):2356-2358. doi: 10.1016/j.neuron.2022.06.015.ABSTRACTNLRP3 is a central driver of neurodegeneration thought to function mainly in microglia. In this issue of Neuron, Panicker et al. (2022) find that NLRP3 is a parkin substrate that contributes significantly to Parkinson's disease pathogenesis by acting in neurons.PMID:35926449 | DOI:10.1016/j.neuron.2022.06.015
• Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson's disease August 4, 2022 Neuron. 2022 Aug 3;110(15):2356-2358. doi: 10.1016/j.neuron.2022.06.015.ABSTRACTNLRP3 is a central driver of neurodegeneration thought to function mainly in microglia. In this issue of Neuron, Panicker et al. (2022) find that NLRP3 is a parkin substrate that contributes significantly to Parkinson's disease pathogenesis by acting in neurons.PMID:35926449 | DOI:10.1016/j.neuron.2022.06.015
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration September 28, 2021 Brain. 2021 Sep 28:awab356. doi: 10.1093/brain/awab356. Online ahead of print.ABSTRACTAberrant activation of the non-receptor kinase c-Abl is implicated in the development of pathogenic hallmarks of Parkinson's disease, such as α-synuclein aggregation and progressive neuronal loss. c-Abl-mediated phosphorylation and inhibition of parkin ligase function lead to accumulation of parkin-interacting substrate that mediates α-synuclein pathology-initiated dopaminergic neurodegeneration. Here we show that, in…
• Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration September 28, 2021 Brain. 2021 Sep 28:awab356. doi: 10.1093/brain/awab356. Online ahead of print.ABSTRACTAberrant activation of the non-receptor kinase c-Abl is implicated in the development of pathogenic hallmarks of Parkinson's disease, such as α-synuclein aggregation and progressive neuronal loss. c-Abl-mediated phosphorylation and inhibition of parkin ligase function lead to accumulation of parkin-interacting substrate that mediates α-synuclein pathology-initiated dopaminergic neurodegeneration. Here we show that, in…
• Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration September 28, 2021 Brain. 2021 Sep 28:awab356. doi: 10.1093/brain/awab356. Online ahead of print.ABSTRACTAberrant activation of the non-receptor kinase c-Abl is implicated in the development of pathogenic hallmarks of Parkinson's disease, such as α-synuclein aggregation and progressive neuronal loss. c-Abl-mediated phosphorylation and inhibition of parkin ligase function lead to accumulation of parkin-interacting substrate that mediates α-synuclein pathology-initiated dopaminergic neurodegeneration. Here we show that, in…
• Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration September 28, 2021 Brain. 2021 Sep 28:awab356. doi: 10.1093/brain/awab356. Online ahead of print.ABSTRACTAberrant activation of the non-receptor kinase c-Abl is implicated in the development of pathogenic hallmarks of Parkinson's disease, such as α-synuclein aggregation and progressive neuronal loss. c-Abl-mediated phosphorylation and inhibition of parkin ligase function lead to accumulation of parkin-interacting substrate that mediates α-synuclein pathology-initiated dopaminergic neurodegeneration. Here we show that, in…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Parkinson’s research in Nigeria March 20, 2022 # # # # In an effort to highlight under-represented populations within the Parkinson’s community world-wide, today we will look at some recent research that has been conducted in the central African republic of Nigeria. Nigeria is a nation of more than 200 million people. Despite a lower general life expectancy rate, the country does have a large Parkinson’s community.…
• Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease February 17, 2022 J Neuroinflammation. 2022 Feb 16;19(1):50. doi: 10.1186/s12974-022-02410-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is characterized by the loss of nigral dopaminergic neurons leading to impaired striatal dopamine signaling, α-synuclein- (α-syn-) rich inclusions, and neuroinflammation. Degenerating neurons are surrounded by activated microglia with increased secretion of interleukin-1β (IL-1β), driven largely by the NLRP3 inflammasome. A critical role for microglial NLRP3 inflammasome activation in the…
• Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease February 17, 2022 J Neuroinflammation. 2022 Feb 16;19(1):50. doi: 10.1186/s12974-022-02410-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is characterized by the loss of nigral dopaminergic neurons leading to impaired striatal dopamine signaling, α-synuclein- (α-syn-) rich inclusions, and neuroinflammation. Degenerating neurons are surrounded by activated microglia with increased secretion of interleukin-1β (IL-1β), driven largely by the NLRP3 inflammasome. A critical role for microglial NLRP3 inflammasome activation in the…
• Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease February 17, 2022 J Neuroinflammation. 2022 Feb 16;19(1):50. doi: 10.1186/s12974-022-02410-4.ABSTRACTBACKGROUND: Parkinson's disease (PD) is characterized by the loss of nigral dopaminergic neurons leading to impaired striatal dopamine signaling, α-synuclein- (α-syn-) rich inclusions, and neuroinflammation. Degenerating neurons are surrounded by activated microglia with increased secretion of interleukin-1β (IL-1β), driven largely by the NLRP3 inflammasome. A critical role for microglial NLRP3 inflammasome activation in the…